INM Stock Catalyst: InMed Pharmaceuticals Announces Preclinical Data for INM-901

Jun 23, 2025 · 7:59pm ET

Company reports significant reduction in neuroinflammation in Alzheimer's disease.

Max move

+123.6%

High of day $5.50

Sparker timei

7:59pm ET

INM · Jun 23, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

InMed Pharmaceuticals Inc. (XNAS: INM) announced preclinical data showing that its drug candidate INM-901 significantly reduces neuroinflammation in Alzheimer's disease ex vivo. The announcement was made following the completion of the preclinical study.

The study demonstrated that INM-901 effectively reduced neuroinflammation, a key factor in the progression of Alzheimer's disease. The company plans to continue research and development efforts to further evaluate the potential of INM-901.

InMed Pharmaceuticals Inc. has a free float of 2,799,500 shares and 2,804,200 shares outstanding.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time INM sparks.

Download Sniper App →

Catch the next INM-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →